There will be about 161,360 new cases of prostate cancer in 2017, and about 26,730 people will die of prostate cancer this year. Prostate cancer is the most common cancer in men in the US alone, reaching about 1 in 7. Unfortunately, diagnosis and treatment methods come with their own risk of side effects. Below we will mention the name of a plant that has recently been discovered that could promote the reduction of tumors in the prostate.
Neem promotes tumor reduction.
Conventional diagnosis for prostate cancer and other tumors usually includes PSA tests and biopsy, which often produce false positives. Treatment may include drugs, surgery, or radiation, including side effects. But researchers have recently discovered a bioactive compound in the Neem tree that can promote tumor shrinkage and help end prostate cancer.
Using the Neem plant for treating prostate cancer.
The neem plant belongs to the mahogany tree family that is originally native to India and the Indian subcontinent. It has been a part of traditional Asian medicine for centuries and is typically used in Indian Ayurvedic medicine. Today, neem leaves and bark have been incorporated into many personal care products such as soaps, toothpaste, skin care, and even dietary supplements.
Eata silver boasts natural anti-inflammatory, anti-fungal, antibacterial, anti-ulcer and anti-cancer properties. New research suggests that a bioactive compound in Neem, known as nimbolide, may have the ability to shrink prostate tumors by up to 70%. During the study, the researchers found that nimbolide also had the ability to suppress metastases by around 50% when taken orally for three months.
“In research we have shown that nimbolide can inhibit the viability of tumor cells – a cellular process that directly affects a cell’s ability to proliferate, grow, divide or repair the components of damaged cells and induce cell death programmed into prostate cancer cells.”
Nimbolide directly affected glutathione reductase, an enzyme responsible for maintaining the antioxidant system in the body that regulates the STAT3 gene. Activation of the STAT3 gene has been reported to contribute to prostate tumor growth and metastasis. We have found that nimbolide can substantially inhibit STAT3 gene activation and thereby abrogate prostate tumor growth and metastasis.